ArticleProstate international2026
Visceral and subcutaneous fat attenuation as prognostic indicators of survival in castration resistant prostate cancer.
Article in Prostate international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While previous studies have examined the link between body fat mass and prognosis in patients with castration-resistant prostate cancer (CRPC), limited evidence exists regarding the prognostic role of specific fat characteristics. We aimed to analyze the relationship between body fat characteristics and cancer-specific survival (CSS) in patients newly diagnosed with CRPC. Methods: Subcutaneous fat attenuation (SAT-HU) and visceral fat attenuation (VAT-HU) were quantified using Hounsfield units (HU) on computed tomography scans at the time of CRPC diagnosis. Average HU values were measured at the L3 vertebra. Patients were stratified into quartiles by SAT-HU and VAT-HU values, and survival outcomes were estimated for each subgroup. Results: Among the 420 patients studied, 340 (81.0%) died from prostate cancer (PC), with a median CSS of 21 months. SAT-HU quartiles were as follows: Q1 (-121.2 to -108.2 HU), Q2 (-108.1 to -102.2 HU), Q3 (-102.1 to -96.0 HU), and Q4 (-95.9 to -52.6 HU). VAT-HU quartiles were as follows: Q1 (-112.6 to -100.9 HU), Q2 (-100.8 to -96.3 HU), Q3 (-96.2 to -89.8 HU), and Q4 (-89.7 to -57.2 HU). The proportion of patients receiving both androgen receptor pathway inhibitor and chemotherapy was the highest in Q1, while chemotherapy alone was the most common in Q4. Median CSS by quartile were Q1: 44, Q2: 24, Q3: 20, and Q4: 12 months for SAT-HU, and Q1: 39, Q2: 29, Q3: 19, and Q4: 13 months for VAT-HU (both Conclusions: Higher SAT-HU and VAT-HU were associated with worse CSS in patients with CRPC. These findings highlight the potential of fat tissue attenuation as a valuable imaging biomarker for prognosis in CRPC, warranting further studies into its clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.